Data di Pubblicazione:
2021
Citazione:
Meta-Analysis of Placebo-Controlled Trials of Levosimendan in Acute Myocardial Infarction / G. Tumminello, A. Cereda, L. Barbieri, G. Biondi-Zoccai, S. Lucreziotti, A. Mafrici, S. Carugo. - In: JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE. - ISSN 2308-3425. - 8:10(2021), pp. 129.1-129.9. [10.3390/jcdd8100129]
Abstract:
The treatment of acute myocardial infarction is early revascularization. Heart failure and cardiogenic shock may complicate acute myocardial infarction despite applying the best available strategy. Levosimendan is a relatively new drug to treat heart failure with a peculiar mechanism of action: calcium sensitization of myocardial fibres. Levosimendan has a direct inotropic effect but also pleiotropic effects; through the K+ATP channel's opening, it also has a vasodilator effect which may participate concretely in the global effects of the drug. The focus of the literature is on the anti-heart failure and anti-cardiogenic shock properties of Levosimendan, but it may have effects also preventing the development of myocardial insufficiency in acute myocardial infarction. The aim of the meta-analysis is to evaluate the effect of Levosimendan on acute myocardial infarction in placebo-controlled trials. Based on the eight studies selected, we found a beneficial effect of Levosimendan on acute and long-term mortality of patients affected by acute myocardial infarction. With caution in interpreting the results of this meta-analysis, our data support the idea that Levosimendan may already have a role in the treatment of acute ischemic heart disease. Further studies specifically designed to investigate the early role in the treatment of ischemic heart failure are needed.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Levosimendan; acute heart failure; acute myocardial infarction
Elenco autori:
G. Tumminello, A. Cereda, L. Barbieri, G. Biondi-Zoccai, S. Lucreziotti, A. Mafrici, S. Carugo
Link alla scheda completa: